News and Trends 8 Oct 2018 Oxford Biotech Launches with €26M to Target ‘Immunometabolism’ Sitryx has launched today with the goal of treating cancer and inflammatory conditions by targeting the metabolism of immune cells, a promising area of research. The new company has kicked off with a €26M Series A round co-led by two specialized investors, SV Health and Sofinnova Partners. Sitryx also has investment from GSK, with […] October 8, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 1 Oct 2018 Cancer-Sniffing Diagnostics Company Secures €43.1M Funding Intoxication is not the only condition that we could diagnose with breathalyzers. The UK-US company Owlstone Medical has secured €43.1M funding to help commercialize its tech that ‘smells’ cancer in your breath. Owlstone’s breathalyzer kit diagnoses conditions by measuring volatile organic compounds in a person’s breath. Disease pathologies affect the types and amounts of these […] October 1, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 20 Sep 2018 RNA Therapy Shows Promise for Treating Liver Cancer British biotech MiNA Therapeutics’ innovative RNA treatment may enhance liver cancer patients’ response to standard cancer therapies, suggest early results from a Phase I/IIa clinical trial. When they received the biotech’s small activating RNA (saRNA) treatment, two patients showed complete responses after being given the cancer treatment sorafenib and one showed a partial response to […] September 20, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 13 Sep 2018 Boehringer Ingelheim Acquires Oncolytic Virus Biotech Company Boehringer Ingelheim is paying €210M to acquire all the remaining shares of ViraTherapeutics, an Austrian biotech company developing oncolytic viral therapies for cancer. ViraTherapeutics develops cancer therapies based on viruses that selectively kill tumor cells, based on the principle that cancer cells show defective mechanisms to defend themselves against viruses that are not able to […] September 13, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 28 Aug 2018 Update: Gilead and Novartis’s CAR T-Cell Therapies Approved in Europe Update: Following on from earlier approvals in the US, the European Commission announced it has given marketing approval for both Gilead’s Yescarta and Novartis’s Kymriah for treatment of patients with various forms of blood cancer. Yescarta (axicabtagene ciloleucel) can be used to treat adults with a relapsed or refractory form of the blood cancer diffuse large […] August 28, 2018 - 4 minutesmins - By Editorial Team Share WhatsApp Twitter Linkedin Email
News and Trends 10 Aug 2018 UK Biotech Raises €73M to Target DNA Repair in Treating Cancer Artios Pharma completed a €73M (£65M) Series B financing round to develop cancer treatments that target DNA repair mechanisms. Cancer occurs when cells in part of the body start dividing uncontrollably as a result of damaged or mutated DNA. In collaboration with Cancer Research UK, Artios Pharma is developing cancer treatments that inhibit proteins involved […] August 10, 2018 - 3 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 26 Jul 2018 Replimune’s €85M IPO set to Boost Oncolytic Immunotherapy Pipeline The US-UK biotech completed its $100M (€85M) IPO on the NASDAQ stock exchange to further develop ‘oncolytic’ immunotherapies that use the herpes virus to target and attack tumor tissue. Replimune’s immunotherapies use the virus to deliver proteins into tumor tissue that help it fuse with the tumor cells. When the virus fuses to tumor cells, it activates […] July 26, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 25 Jul 2018 Austrian Researchers Grow Cancerous Mini Brains in a Dish Researchers in Vienna are growing mini brains that mimic the onset and development of brain cancer, which could be used to compare the efficacy of different treatments. Because of their cellular complexity, brain cancers have been difficult to study in animals. Glioblastoma, the most aggressive form of brain cancer, is particularly difficult to treat because […] July 25, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
Interview 24 Jul 2018 Meet the Dutch Scientists who Invented Keytruda, “The President’s Drug” Known for curing US President Jimmy Carter’s cancer, Keytruda continues to benefit many other cancer patients. The inventors told us their story, from the drug’s early days to their current role as executives of the biotech unicorn Aduro. Since 2014, the cancer drug Keytruda, also known as pembrolizumab, continues to be widely sought after due […] July 24, 2018 - 6 minutesmins - By Editorial Team Share WhatsApp Twitter Linkedin Email
News and Trends 12 Jul 2018 Collaboration Worth Over €1Bn Could Give Rise to New Cancer Immunotherapies Genmab is partnering with the German company Immatics to develop immunotherapies directed against three cancer targets. Genmab has offered Immatics, based in Tuebingen, Germany, an upfront payment of $54M (€46M) in addition to milestone payments worth up to $550M (€470M) for each product. Genmab has a market cap of €60Bn ($70Bn). The funding will be […] July 12, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jul 2018 Radioactive Nanoparticle Could Improve Cancer Diagnoses Isotopia Molecular Imaging, an Israeli company, is developing a radioactive marker made of gold nanoparticles to detect cancer more accurately than with current diagnostic tools. PET and CT scans are two types of X-ray tests that use small quantities of radioactive materials, called contrast agents, to help visualize and assess organ and tissue function. These […] July 11, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 29 Jun 2018 Update: Yet Another ADC Company Makes Bank, This Time in Series B Update (29.06.2018): NBE Therapeutics has extended its Series B fundraising round by 20M CHF (€17.3M), reaching a total of 40M CHF (€34.6M) for the round. Novo Holdings joins the Boehringer Ingelheim Venture Fund and the PPF Capital Partners Fund as a major shareholder of the Swiss biotech, which continues to develop its ADCs for improved […] June 29, 2018 - 3 minutesmins - By Editorial Team Share WhatsApp Twitter Linkedin Email